Research review · Sources checked October 15, 2026

Published February 14, 2026 · Updated October 31, 2026

BPC-157: what the research shows

BPC-157 is a synthetic peptide described in the literature as derived from a naturally occurring gastric peptide. It is not an FDA-approved drug, and almost all of the published evidence comes from animal studies.[1][2]

Regulatory status

No FDA-approved drug product contains BPC-157; a search of Drugs@FDA returns no approved application.[2] FDA lists BPC-157 among bulk drug substances that were placed in category 2 (“may present significant safety risks”) under its 503A/503B compounding interim policies and whose nominations were later withdrawn. FDA’s stated concerns are possible immunogenicity, peptide-related impurities, difficulty characterizing the active ingredient, and “no, or only limited, safety-related information” for the proposed routes, so the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans.”[3]

A 2025 systematic review also notes that BPC-157 is banned in professional sport.[1]

Update, October 28, 2026: HHS made public a draft enforcement-discretion policy that lists BPC-157 among six peptides (the others are epitalon, KPV, MOTS-c, semax and TB-500). HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound these peptides under 10 conditions.[7] For BPC-157, Appendix B names BPC-157 acetate, for subcutaneous, intramuscular, oral and topical use only. Oral forms also need documentation of adequate oral bioavailability in humans.[7] The conditions include bulk powder from an FDA-registered facility with a certificate of analysis, one listed active ingredient per product, reporting of serious adverse events and a patient-specific prescription.[7] HHS calls the document a draft, open to comment on regulations.gov (Docket No. HHS-OASH-2026-0496) until 2 weeks after its October 30, 2026 Federal Register publication (November 13, 2026, per regulations.gov), and says it is not binding and may be revisited if a safety signal or quality problem arises.[7] This is not an FDA approval: compounded drugs are not reviewed by FDA for safety or effectiveness, and the policy records that FDA’s drug center recommended against listing BPC-157.[7] For what it does and doesn’t change, see our FDA peptide policy explainer. This summary is not legal advice.

What the evidence base looks like

A 2025 systematic review in orthopaedic sports medicine screened 544 records and included 36 studies: 35 preclinical and 1 clinical. In animal models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone injuries. The authors rated the evidence as level IV and V and found no clinical safety data.[1]

A 2026 narrative review of approved and unapproved sports-medicine peptides reached a similar conclusion for the unapproved group: favorable results in animal models, scarce rigorous human safety data, and potential for serious harm.[4]

Human reports

• Knee pain chart review (2021). A retrospective review at one clinic phoned 16 patients who had received intra-articular BPC-157 (12 alone, 4 combined with thymosin beta-4). Pain relief was self-reported by telephone, with no validated outcome tools and no control group.[5]
• Intravenous safety pilot (2025). Two adults, both of whom had used intravenous BPC-157 before, received 10 mg and then 20 mg infusions. No changes in the measured heart, liver, kidney, thyroid, or glucose markers and no side effects were reported.[6] Two participants cannot establish safety.

Who is using BPC-157? A 2026 study of clinical notes

The short answer: documented BPC-157 use in US medical records rose sharply from 2020 to 2026, mostly for pain and injuries, and about half of users were taking something else at the same time. The study counts use; it cannot show whether BPC-157 works or is safe.[8]

The analysis was posted on September 7, 2026 as a preprint, which means it has not been peer reviewed. AJMC covered it on October 29 and describes the researchers as working at the data analytics firm nference.[8][9] Because BPC-157 is not an approved drug and has no prescription code, the team used large language models, checked by physicians, to read de-identified clinical notes from a US health-record network (more than 15 million records, per AJMC).[8][9] What the abstract reports:[8]

• How many. 1,536 patients had a note mentioning BPC-157; 1,039 of them (67.6%) had documented use. New confirmed users per quarter rose 33-fold between 2020 and 2026.[8]
• Who. The share of men among new users rose from 57% in 2020 to 70% in 2026, and mean age fell from 55 to 49. Of 972 users with race recorded, 95.9% were White, compared with 78% of the wider patient network.[8]
• Why. Pain was the most common recorded reason (33% of users), then stomach and gut problems such as reflux, inflammatory bowel disease or gastritis (14%), past injury (11%) and healing after surgery (10%).[8]
• Where from. Only 205 users (19.7%) had a source recorded. Among them, 36% got it from compounding pharmacies and 35% from gray-market peptide sellers.[8]
• Other treatments. 50.5% used at least one other drug alongside it, most often testosterone (17.0%), NSAID pain relievers (14.7%), TB-500 (12.9%) or corticosteroids (11.7%). Physical therapy (15.3%) and surgery (12.6%) were also recorded.[8]
• Late to the doctor. In 80 users with a known start date, use began a mean of 60 days before a clinician first wrote it down.[8]
• Reported results. Of 354 users whose notes recorded a direction of change, 79% were noted as improved and 5% as worse; no direction was recorded for 685 of the 1,039 (65.9%).[8]
• Side effects. Notes recorded neuropsychiatric (1.4%), injection-site (1.4%) and gastrointestinal (1.3%) events; the authors say side effects were likely under-reported.[8]

Limits. The authors write that these reports “cannot establish efficacy or distinguish BPC-157 effects from peptide stacking, other co-treatments, non-drug interventions, placebo effects or selection, reporting and confirmation biases.”[8] AJMC reports that Flynn McGuire, MD, of the University of Utah, who studies BPC-157 and was not involved, noted the lack of a placebo or untreated comparison group, of a standard dose or product, and of consistent outcome measures.[9] The study leader, Venky Soundararajan, PhD, cautioned that most physicians do not routinely ask about BPC-157, so use is likely undercounted, AJMC reports.[9] The preprint’s full text was not available to us, so we have not read its funding or conflict-of-interest statement; the figures above are from its abstract.[8]

Our analysis: as of October 31, 2026, this is the first count we have found of BPC-157 use drawn from medical records, and it shows people are already using it widely, often alongside other drugs, before any human trial has tested it. The “79% improved” figure covers only about a third of users, is mostly what patients told their clinician, and has no comparison group, so it is not evidence that BPC-157 works. If you use BPC-157, tell your clinician, including anything you take with it; side effects can be reported to FDA’s MedWatch program.[8][3]

Mechanism claims

Reviews describe proposed effects on growth hormone receptor expression, angiogenesis pathways, and inflammatory cytokines, based on cell and animal work. The systematic review reports a half-life of under 30 minutes, with hepatic metabolism and renal clearance, from preclinical data.[1]

What is not known

There are no randomized controlled trials in humans, no established human dose, and no long-term safety data. Products sold online are unregulated, and FDA specifically flags impurity and characterization problems for this peptide.[1][3]

This page summarizes published research and regulatory documents. It is not medical advice and does not recommend using, sourcing, or dosing any of these substances.